DARTFORD, England, SANTIAGO, Chile and BERLIN, August 19, 2015 /PRNewswire/ --
Neptune Pharma's Azasure, a highly successful and much anticipated generic version of Benchmark Holding's Salmosan has been approved for use on Sea Lice in the Chilean Salmon market.
Neptune Pharma ( http://www.neptunepharma.com ) announced today their highly successful generic sea lice product containing Azamethiphos for use on farmed salmon was approved by Chile's Servicio Agrícola y Ganadero (SAG) in July 2015. Azasure will be available in Chile by August 2015.
Since the Norwegian launch of Azasure in January 2014, Azasure has taken a significant market share from Benchmark Holding's Salmosan. In 2014, Azasure's own market share rose to above 60%.
Neptune Pharma hopes to replicate the success of their 2014 Norwegian launch in Chile and gain significant market share from their competitors by working closely with their commercial partner Europharma Chile.
Currently two companies have Azamethiphos based treatments licensed in Chile: Benchmark Holdings Plc's product Salmosan, renamed Bylice for the Chilean market & also Recalcine's CalFree.
"The launch of Azasure in Chile signals the end to many years of challenging work within our organisation globally. After such a long wait, we're happy to get from the regulatory and planning phase into the commercial phase," says Adrian Endacott, Chief Executive Officer of Neptune Pharma.
Contact:
Neptune Pharma Limited
phone: +44-845-123-3834
email: info@neptunepharma.com
